Novel concepts in the pathophysiology and treatment of functional dyspepsia

Gut. 2020 Mar;69(3):591-600. doi: 10.1136/gutjnl-2019-318536. Epub 2019 Nov 29.

Abstract

Emerging data increasingly point towards the duodenum as a key region underlying the pathophysiology of functional dyspepsia (FD), one of the most prevalent functional GI disorders. The duodenum plays a major role in the control and coordination of gastroduodenal function. Impaired duodenal mucosal integrity and low-grade inflammation have been associated with altered neuronal signalling and systemic immune activation, and these alterations may ultimately lead to dyspeptic symptoms. Likely luminal candidates inducing the duodenal barrier defect include acid, bile, the microbiota and food antigens although no causal association with symptoms has been convincingly demonstrated. Recognition of duodenal pathology in FD will hopefully lead to the discovery of new biomarkers and therapeutic targets, allowing biologically targeted rather than symptom-based therapy. In this review, we summarise the recent advances in the diagnosis and treatment of FD with a focus on the duodenum.

Keywords: duodenal mucosa; functional bowel disorder; functional dyspepsia; intestinal permeability.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bile Acids and Salts / metabolism
  • Brain / physiopathology
  • Duodenum / immunology
  • Duodenum / metabolism
  • Duodenum / microbiology
  • Duodenum / physiopathology*
  • Dysbiosis / drug therapy
  • Dysbiosis / physiopathology
  • Dyspepsia / diagnosis
  • Dyspepsia / drug therapy*
  • Dyspepsia / etiology*
  • Dyspepsia / physiopathology
  • Gastric Emptying
  • Humans
  • Neurotransmitter Agents / therapeutic use
  • Probiotics / therapeutic use
  • Proton Pump Inhibitors / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Bile Acids and Salts
  • Neurotransmitter Agents
  • Proton Pump Inhibitors